| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.AMJCARD.2005.12.018 |
| P698 | PubMed publication ID | 16387575 |
| P50 | author | Elizabeth Barrett-Connor | Q37322423 |
| Robert A Kloner | Q56014628 | ||
| Irwin Goldstein | Q60058071 | ||
| Francesco Montorsi | Q67191520 | ||
| Murray A. Mittleman | Q87967265 | ||
| P2093 | author name string | Peter Ganz | |
| Arthur L. Burnett | |||
| Vivian Fonseca | |||
| Ajay Nehra | |||
| Graham Jackson | |||
| Raymond Rosen | |||
| Ridwan Shabsigh | |||
| Piero Montorsi | |||
| Richard Sadovsky | |||
| Culley Carson | |||
| Stuart Katz | |||
| Judd E. Hollander | |||
| John B. Kostis | |||
| Dimitris Hatzichristou | |||
| Adolph Hutter | |||
| Andre Guay | |||
| Kevin Billups | |||
| Melvin Cheitlin | |||
| Robert Debusk | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sexual dysfunction | Q1137463 |
| P304 | page(s) | 85-93 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Sexual Dysfunction and Cardiac Risk (the Second Princeton Consensus Conference) | |
| P478 | volume | 96 |
| Q38067490 | Assessment of EndoPAT scores in men with vasculogenic and non-vasculogenic erectile dysfunction |
| Q37157274 | Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist |
| Q46107133 | Cardiovascular risk engines can help in selecting patients to be evaluated by dynamic penile color doppler ultrasound. |
| Q38262087 | Chronic bladder ischemia and oxidative stress: new pharmacotherapeutic targets for lower urinary tract symptoms |
| Q33752512 | Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? |
| Q55050673 | ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology |
| Q34700728 | Endothelin-1 induces contraction of female rat internal pudendal and clitoral arteries through ET(A) receptor and rho-kinase activation |
| Q37502288 | Epidemiology of male sexual dysfunction |
| Q35977540 | Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment |
| Q36474164 | Erectile dysfunction and mortality |
| Q63408534 | Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes |
| Q80866828 | Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study |
| Q34433634 | Female sexual dysfunction: therapeutic options and experimental challenges. |
| Q93336527 | High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis |
| Q37886052 | Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health |
| Q39849053 | Pharmacotherapy of Vasospastic Angina |
| Q42500704 | Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study |
| Q38832052 | Routine cardiac assessment is not necessary for all patients with erectile dysfunction |
| Q38177225 | Sexual activity and ischemic heart disease |
| Q38209723 | Sexual dysfunction in heart failure patients |
| Q37697909 | Sexuality and elderly with chronic diseases: A review of the existing literature. |
| Q53042790 | Significance of platelet distribution width as a severity marker of erectile dysfunction. |
| Q37833959 | Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action |
| Q47667272 | The Role of Nitroglycerin and Other Nitrogen Oxides in Cardiovascular Therapeutics |
| Q39143822 | The dangers of sexual enhancement supplements and counterfeit drugs to "treat" erectile dysfunction |
| Q37882114 | The link between erectile and cardiovascular health: the canary in the coal mine |
| Q45987400 | The prevalence and clinical relevance of sexual dysfunction in women and men with chronic heart failure. |
| Q37321940 | The use of phosphodiesterase 5 inhibitors with concomitant medications. |
| Q37427312 | Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction |
| Q26782134 | Translational Research and Functional Changes in Voiding Function in Older Adults |
| Q37466573 | Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil |
| Q33571010 | Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence |
Search more.